Dogwood Therapeutics Q1 Net Loss $(4.99)M; Going Concern Doubt
Dogwood Therapeutics reported a net loss of $(4.99) million for Q1 2026, an improvement from $(10.92) million in Q1 2025, with basic and diluted net loss per share improving to $(0.15). Despite an increase in cash and cash equivalents to $13.23 million, the company disclosed substantial doubt about its ability to continue as a going concern beyond Q4 2026 without additional financing. Operating expenses increased to $5.08 million, and the company continues to advance its drug candidates, with Halneuron® Phase 2b results expected in Fall 2026.
Key Highlights
- Substantial doubt about the Company's ability to continue as a going concern beyond Q4 2026.
- Net loss for Q1 2026 improved to $(4.99) million from $(10.92) million in Q1 2025.
- Basic and diluted net loss per common share improved to $(0.15) from $(8.45) year-over-year.
- Cash and cash equivalents increased to $13.23 million as of March 31, 2026, from $6.52 million.
- Operating expenses rose to $5.08 million in Q1 2026 from $4.43 million in Q1 2025.
- Net cash provided by financing activities was $11.29 million, primarily from common stock issuance.
- Halneuron® Phase 2b CINP study top-line results are expected in Fall 2026.
- Goodwill and IPR&D assets are at risk of future impairment despite no current impairment.
Price Impact
More from DWTX
Dogwood Therapeutics Reports Q3 Net Loss of $4.88M, Down from $15.74M
Dogwood Therapeutics Q2 Net Loss $11.5M; Halneuron® Phase 2b on track
Dogwood Therapeutics Halneuron® Phase 2b On Track; Antiviral Deal Up To $100M